AstraZeneca has entered into a global exclusive license agreement with KYM Biosciences for CMG901, which is being investigated as a gastric cancer treatment.
AstraZeneca announced a global exclusive license agreement deal with KYM Biosciences, a joint venture established by affiliates of Keymed Biosciences and Lepu Biopharma, on Feb. 23, 2023. The deal is centered around CMG901, an antibody drug conjugate (ADC) currently being evaluated as a potential treatment for gastric cancer.
CMG901 is a novel ADC targeting Claudin 18.2, consisting of an anti-Claudin 18.2 monoclonal antibody, a protease-degradable linker, and a cytotoxic small molecule monomethyl auristatin E. Under the agreement, AstraZeneca will pay KYM $63 million upfront for the rights to CMG901, with an additional $1.1 billion and low-double digit royalties contingent on various development and sales-based milestones. The deal is expected to close in the second half of 2023.
According to a company press release, AstraZeneca will be responsible for the research, development, manufacture, and commercialization of CMG901. CMG901 is currently being investigated in a Phase I clinical trial as a treatment for cancers with tumors expressing Claudin 18.2, which includes gastric cancers; preliminary results demonstrate early signs of anti-tumor activity across the tested dose levels.
“We are excited by the opportunity to accelerate the development of CMG901, a potential new medicine for patients with Claudin 18.2-expressing cancer,” said Puja Sapra, senior vice-president, Biologics Engineering & Oncology Targeted Delivery, Oncology R&D, AstraZeneca, in the release. “CMG901 strengthens our growing pipeline of antibody drug conjugates and supports our ambition to expand treatment options and transform outcomes for patients with gastrointestinal cancers.”
Source: AstraZeneca
Kyron.bio Raises €5.5M to Advance Precision Glycan Engineering for Safer Antibody Therapeutics
May 28th 2025Funding will support the company’s efforts to refine its proprietary glycan-engineering platform, expand its scientific and operational team, and advance preclinical studies of its engineered biologics.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.